ABOUT BRCA

Men and women who have a BRCA1 or BRCA2 gene mutation have an increased risk for developing certain cancers, including breast, ovarian, pancreatic, and prostate. Research suggests that women with BRCA mutations have up to a 75% lifetime risk of developing breast cancer, and up to a 50% lifetime risk of developing ovarian cancer. Men with a BRCA mutation have up to a 40% lifetime risk of developing aggressive prostate cancer. It is estimated that 25 million people worldwide have a BRCA mutation, and only 10% are aware they carry this hereditary gene mutation.

ABOUT THE BASSER CENTER

Pioneering the Fight Against Hereditary Cancer

Founded in 2012 by Mindy and Jon Gray, the Basser Center for BRCA at Penn Medicine's Abramson Cancer Center is the world's first comprehensive center dedicated to BRCA-related cancer research, treatment, and prevention.

Advancing Discovery

The Basser Center has become a global leader in BRCA-related cancer research, bringing together experts in basic, translational, and clinical science to accelerate breakthroughs from the laboratory to patients.

Fueling Collaboration

Through investments in research, education, and outreach at Penn and around the world, Basser supports the brightest minds and boldest ideas to drive progress.

Intercepting Cancer

Our work spans early detection, interception, treatment, survivorship, and expanded access to genetic counseling and testing. In 2022, we launched the Basser Cancer Interception Institute to advance innovative approaches that aim to stop cancer before it starts.

OUR HOPE

That the Basser Center will eliminate BRCA-related cancers and, in doing so, provide a road map for curing other genetic diseases. Funds raised through this event will help to quicken the pace of lifesaving medical discoveries.